NIH Cloud PlatformInteroperability Effort



Multicenter Study of Hydroxyurea (MSH)

phs002348.v1.p1dbGapdbGap FHIR


This study aimed to determine whether or not treatment with hydroxyurea titrated to maximum tolerated doses would reduce the frequency of vaso-occlusive (painful) crises by at least 50% in 299 men and women between 18 and 50 years old with a diagnosis of sickle cell anemia by gel electrophoresis conducted by a Core Laboratory. A secondary objective investigated correlations of fetal hemoglobin (HbF) levels and other patient or treatment characteristics with the occurrence of vaso-occlusive (painful) crises, and the effect of treatment on the quality of life.

This controlled trial made hydroxyurea the first drug of proven benefit in preventing vaso-occlusive pain crisis and acute chest syndrome caused by sickle cell disease, with additional findings including reduced mortality in adult patients taking hydroxyurea for frequent painful sickle cell episodes after 9 of years follow-up. No significant side-effects of hydroxyurea therapy were noted.

Instructions for requesting individual-level data are available on BioData Catalyst at Apply for data access in dbGaP. Upon approval, users may begin accessing requested data in BioData Catalyst. For questions about availability, you may contact the BioData Catalyst team at


Consent CodesGRU
Focus / DiseasesAnemia, Sickle Cell
Study DesignClinical Trial
Data Types--

Applying For Access

dbGaP FAQdbGaP Access Request Video Tutorial